Abstract
Positron emission tomography (PET) imaging of Alzheimers Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest. Given the short half-life of the most popular positron emitter currently used (18F; ∼120 min.) extremely rapid and efficient radiochemistry methods are needed to ensure required compounds are prepared and purified for administration within the 2-3 half life practical limit. Recent efforts to combine microwave mediated synthesis with advanced catalysis in the synthesis of specific categories of AD imaging agents will be presented.
Keywords: F18, PET, imaging agents, microwave, synthesis, radiochemistry
Current Alzheimer Research
Title: Microwave Accelerated Synthesis of PET Image Contrast Agents for AD Research
Volume: 7 Issue: 3
Author(s): A.E. Kallmerten and G.B. Jones
Affiliation:
Keywords: F18, PET, imaging agents, microwave, synthesis, radiochemistry
Abstract: Positron emission tomography (PET) imaging of Alzheimers Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest. Given the short half-life of the most popular positron emitter currently used (18F; ∼120 min.) extremely rapid and efficient radiochemistry methods are needed to ensure required compounds are prepared and purified for administration within the 2-3 half life practical limit. Recent efforts to combine microwave mediated synthesis with advanced catalysis in the synthesis of specific categories of AD imaging agents will be presented.
Export Options
About this article
Cite this article as:
Kallmerten A.E. and Jones G.B., Microwave Accelerated Synthesis of PET Image Contrast Agents for AD Research, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050830
DOI https://dx.doi.org/10.2174/156720510791050830 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Eating Disorders in Adolescents (Guest Editors: Julie Lesser and Kathleen Kara Fitzpatrick)]
Adolescent Psychiatry Aromatherapy and the Central Nerve System (CNS): Therapeutic Mechanism and its Associated Genes
Current Drug Targets Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Development of New Drugs for COPD
Current Medicinal Chemistry The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine A Sweeping Role for MicroRNAs in Neuronal Disease, Vascular Disorders, and as Prognostic Indicators
Current Neurovascular Research A Novel Strategy to Manage Tolerance to Lamotrigine in Bipolar II Depression
Letters in Drug Design & Discovery Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases
Current Protein & Peptide Science GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Current Drug Targets Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry The Natural Diatomite from Çaldıran-Van (Turkey): Electroanalytical Application to Antimigraine Compound Naratriptan at Modified Carbon Paste Electrode§
Combinatorial Chemistry & High Throughput Screening Drug Development and PET-Diagnostics for Alzheimers Disease
Current Medicinal Chemistry Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects
Current Cancer Drug Targets Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Hypericin Ameliorates Maternal Separation-Induced Cognitive Deficits and Hippocampal Inflammation in Rats
Mini-Reviews in Medicinal Chemistry First Girgensohnine Analogs Prepared Through InCl<sub>3</sub>-catalyzed Strecker Reaction and their Bioprospection
Current Organic Synthesis Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS
CNS & Neurological Disorders - Drug Targets